Intratumoral therapy, involving direct drug injection into tumors, holds promise for solid cancer treatment.
However, its clinical success has been limited due to challenges in precise drug delivery and rapid drug dispersion from the injection site.
A research team from Mass General Brigham, in collaboration with the Koch Institute for Integrative Cancer Research, has developed an innovative gel delivery system to address these limitations.
This injectable gel solidifies upon delivery, incorporates an imaging agent for visualization via CT scans, and can maintain a high drug concentration for controlled, slow release.
The Gel’s Potential Impact
Published in Advanced Healthcare Materials, this study demonstrates that the gel-delivered immune-stimulating drug, imiquimod, in combination with checkpoint inhibitor therapy, induced tumor regression and prolonged survival in mouse models of colon and breast cancer, typically resistant to checkpoint inhibitor therapy.
Additionally, this treatment seemed to prime the immune system to detect and attack distant untreated tumors, suggesting its potential as a therapy for metastatic cancers.
Overcoming Key Challenges
The gel’s design required it to transition from a liquid state at room temperature for injectability to a solid state at body temperature inside the tumor, creating a drug-releasing depot.
It also had to retain drug encapsulation and delivery capability while incorporating an imaging agent.
Results and Implications: The gel-treated mice exhibited an impressive response, with complete regression of both treated and distant tumors in responders, simulating a metastasis model.
In the colon cancer model, 46% of mice survived when receiving the combined therapies, and 20% of mice in the breast cancer model experienced survival benefits.
The Road to Clinical Application: While the researchers aim to advance this technology to clinical use, further safety testing and evaluation with a broader range of drugs are required.
The gel’s potential to simplify cancer treatment by enabling single-injection therapies for challenging-to-treat cancers holds significant promise.
Conclusion
The development of an injectable, solidifying gel delivery system represents a breakthrough in intratumoral cancer immunotherapy.
This innovative approach not only addresses drug delivery challenges but also enhances the therapeutic efficacy against resistant solid cancers.
The study offers hope for improved cancer treatments, particularly for patients with tumors that are difficult to manage using current therapies.
If you care about cancer, please read studies about Catching the silent killer: a new study on esophageal cancer and findings of New trick knocks out tough guy prostate cancer.
For more information about cancer, please see recent studies about Think twice before using artificial sweeteners: they might increase cancer risk and results showing that Oxford study links lower meat consumption to reduced cancer risk.
The research findings can be found in Advanced Healthcare Materials.
Follow us on Twitter for more articles about this topic.
Copyright © 2023 Knowridge Science Report. All rights reserved.
